680 filings
Page 23 of 34
6-K
cqxc5pmx20pris lhbh
13 Dec 16
RedHill Biopharma Announces Positive and Unanimous DSMB Recommendation for Continuation of Phase III Study with RHB-104 for Crohn’s Disease
12:00am
6-K
e04rsw5dw6ogz
12 Dec 16
RedHill Biopharma Announces Phase IIa 48-Week Final Results Further Supporting Potential of RHB-104 in Multiple Sclerosis
12:00am
6-K
e7161u
5 Dec 16
RedHill Biopharma to Present at the Jefferies Microbiome Summit
12:00am
6-K
ipihftw6rs
21 Nov 16
RedHill Biopharma Announces YELIVA™ (ABC294640) Poster Presentation at the 2016 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
12:00am
6-K
5iwaj4wciak pbm8aiy
16 Nov 16
RedHill Biopharma to Present at the German Equity Forum 2016
12:00am
6-K
i8yknkcfl 6peh18lyn
14 Nov 16
Current report (foreign)
12:00am
6-K
dln94o anohgp
10 Nov 16
RedHill Biopharma Reports Positive FDA Type B Meeting on RHB-105 for H. pylori Infection Ahead of Confirmatory Phase III Study
12:00am
6-K
g9gt4
7 Nov 16
Current report (foreign)
12:00am
6-K
p2m0hgg
7 Nov 16
RedHill Biopharma to Present at the Jefferies 2016 London Healthcare Conference
12:00am
6-K
rptyjlmctqupz86k
3 Nov 16
RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA® and Expected Timing of Top-Line Results
12:00am
6-K
wkuojde3w10h1na2lq9
2 Nov 16
RedHill Biopharma Announces Withdrawal of Public Offering of its American Depositary Shares
12:00am
6-K
t8w 64k69p
1 Nov 16
RedHill Biopharma Announces Proposed Public Offering of its American Depository Shares
12:00am
6-K
rqs6x
31 Oct 16
RedHill Biopharma to Present at the BIO-Europe 2016 Conference
12:00am
6-K
5jwb hhg7
18 Oct 16
RedHill Biopharma Announces Allowance of a Patent in Japan Supporting RHB-104 for Multiple Sclerosis
12:00am
6-K
nwwufjbkvgj mnr6v
13 Oct 16
RedHill Biopharma to Present at the BIO Investor Forum 2016
12:00am
6-K
kzykem98x8vbzbrcq9u8
6 Oct 16
RedHill Biopharma Provides Progress Update on RHB-104 Phase III Crohn’s Disease Program and Introduces Option for Early Stop for Success in Q2/2017
12:00am
6-K
3rktitug
6 Oct 16
Current report (foreign)
12:00am
6-K
debqqmjhgy8qt5j9
5 Oct 16
RedHill Biopharma Announces Initiation of Phase II Study with YELIVA™ in Hepatocellular Carcinoma at the Medical University of South Carolina
12:00am
6-K
ffuqs 2wg9qb
27 Sep 16
RedHill Biopharma to Present at the BioNetwork West 2016 Partnering Summit
12:00am
6-K
c5ofhzz7 gxwdhho5
21 Sep 16
RedHill Biopharma and IntelGenx Announce RIZAPORT® Commercialization Term Sheet with Pharmatronic Co. for Korea
12:00am